Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.
Standard
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. / Pui, C-H; Chessells, J M; Camitta, B; Baruchel, A; Biondi, A; Boyett, J M; Carroll, A; Eden, O B; Evans, W E; Gadner, H; Harbott, J; Harms, D O; Harrison, C J; Harrison, P L; Heerema, N; Janka-Schaub, Gritta; Kamps, W; Masera, G; Pullen, J; Raimondi S, C; Richards, S; Riehm, H; Sallan, S; Sather, H; Shuster, J; Silverman, L B; Valsecchi, M G; Vilmer, E; Zhou, Y; Gaynon, P S; Schrappe, M.
In: LEUKEMIA, Vol. 17, No. 4, 4, 2003, p. 700-706.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.
AU - Pui, C-H
AU - Chessells, J M
AU - Camitta, B
AU - Baruchel, A
AU - Biondi, A
AU - Boyett, J M
AU - Carroll, A
AU - Eden, O B
AU - Evans, W E
AU - Gadner, H
AU - Harbott, J
AU - Harms, D O
AU - Harrison, C J
AU - Harrison, P L
AU - Heerema, N
AU - Janka-Schaub, Gritta
AU - Kamps, W
AU - Masera, G
AU - Pullen, J
AU - Raimondi S, C
AU - Richards, S
AU - Riehm, H
AU - Sallan, S
AU - Sather, H
AU - Shuster, J
AU - Silverman, L B
AU - Valsecchi, M G
AU - Vilmer, E
AU - Zhou, Y
AU - Gaynon, P S
AU - Schrappe, M
PY - 2003
Y1 - 2003
N2 - To assess the clinical heterogeneity among patients with acute lymphoblastic leukemia (ALL) and various 11q23 abnormalities, we analyzed data on 497 infants, children and young adults treated between 1983 and 1995 by 11 cooperative groups and single institutions. The substantial sample size allowed separate analyses according to age younger or older than 12 months for the various cytogenetic subsets. Infants with t(4;11) ALL had an especially dismal prognosis when their disease was characterized by a poor early response to prednisone (P=0.0005 for overall comparison; 5-year event-free survival (EFS), 0 vs 23+/-+/-12% s.e. for those with good response), or age less than 3 months (P=0.0003, 5-year EFS, 5+/-+/-5% vs 23.4+/-+/-4% for those over 3 months). A poor prednisone response also appeared to confer a worse outcome for older children with t(4;11) ALL. Hematopoietic stem cell transplantation failed to improve outcome in either age group. Among patients with t(11;19) ALL, those with a T-lineage immunophenotype, who were all over 1 year of age, had a better outcome than patients over 1 year of age with B-lineage ALL (overall comparison, P=0.065; 5-year EFS, 88+/-+/-13 vs 46+/-14%). In the heterogeneous subgroup with del(11)(q23), National Cancer Institute-Rome risk criteria based on age and leukocyte count had prognostic significance (P=0.04 for overall comparison; 5-year EFS, 64+/-+/-8% (high risk) vs 83+/-+/-6% (standard risk)). This study illustrates the marked clinical heterogeneity among and within subgroups of infants or older children with ALL and specific 11q23 abnormalities, and identifies patients at particularly high risk of failure who may benefit from innovative therapy.
AB - To assess the clinical heterogeneity among patients with acute lymphoblastic leukemia (ALL) and various 11q23 abnormalities, we analyzed data on 497 infants, children and young adults treated between 1983 and 1995 by 11 cooperative groups and single institutions. The substantial sample size allowed separate analyses according to age younger or older than 12 months for the various cytogenetic subsets. Infants with t(4;11) ALL had an especially dismal prognosis when their disease was characterized by a poor early response to prednisone (P=0.0005 for overall comparison; 5-year event-free survival (EFS), 0 vs 23+/-+/-12% s.e. for those with good response), or age less than 3 months (P=0.0003, 5-year EFS, 5+/-+/-5% vs 23.4+/-+/-4% for those over 3 months). A poor prednisone response also appeared to confer a worse outcome for older children with t(4;11) ALL. Hematopoietic stem cell transplantation failed to improve outcome in either age group. Among patients with t(11;19) ALL, those with a T-lineage immunophenotype, who were all over 1 year of age, had a better outcome than patients over 1 year of age with B-lineage ALL (overall comparison, P=0.065; 5-year EFS, 88+/-+/-13 vs 46+/-14%). In the heterogeneous subgroup with del(11)(q23), National Cancer Institute-Rome risk criteria based on age and leukocyte count had prognostic significance (P=0.04 for overall comparison; 5-year EFS, 64+/-+/-8% (high risk) vs 83+/-+/-6% (standard risk)). This study illustrates the marked clinical heterogeneity among and within subgroups of infants or older children with ALL and specific 11q23 abnormalities, and identifies patients at particularly high risk of failure who may benefit from innovative therapy.
M3 - SCORING: Zeitschriftenaufsatz
VL - 17
SP - 700
EP - 706
JO - LEUKEMIA
JF - LEUKEMIA
SN - 0887-6924
IS - 4
M1 - 4
ER -
